Table 6. Spearman rank coefficients for clinical parameters and metabolites those showed a statistically significant difference between subjects with and without NAFLD having elevation of ALT in MS.
| Niacinamide | Inosine | Acetylcarnitine | |
|---|---|---|---|
| BMI | -0.001 | 0.181 | -0.016 |
| WC | -0.082 | 0.182 | -0.027 |
| Hypertension | -0.021 | 0.180 | 0.113 |
| Dyslipidemia | -0.091 | -0.227 | 0.189 |
| IGT | -0.132 | -0.173 | 0.445* |
| ALT | 0.368* | 0.374* | -0.252 |
| AST | 0.302 | 0.253 | -0.259 |
| GGT | 0.151 | -0.276 | -0.079 |
| UA | -0.133 | -0.018 | 0.101 |
| HOMA-IR | 0.269 | 0.472** | -0.222 |
| NAFIC score | 0.350* | 0.189 | -0.207 |
| FIB-4 index | 0.120 | 0.060 | -0.310 |
| Fatty liver | 0.113 | 0.229 | 0.113 |
| NAFLD with elevation of ALT | 0.368* | 0.421* | -0.355* |
*p < 0.05
**p < 0.01.
ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; GGT, gamma-glutamyl transpeptidase; HOMA-IR: homeostasis model assessment of insulin resistance; IGT, impaired glucose tolerance; MS, metabolic syndrome; NAFLD, nonalcoholic fatty liver disease; UA, uric acid; WC, waist circumference.